SIP
TPST icon

Stoneridge Investment Partners’s Tempest Therapeutics TPST Stock Holding History

Stoneridge Investment Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3
Closed -$14K – 242
2017
Q4 		$14K Sell
3
-1
-25% -$4.2K ﹤0.01% 220
2017
Q3 		$16K Hold
4
– – ﹤0.01% 237
2017
Q2 		$17K Sell
4
-8
-67% -$33.9K ﹤0.01% 250
2017
Q1 		$67K Sell
12
-5
-29% -$23.3K 0.01% 304
2016
Q4 		$76K Hold
17
– – 0.01% 282
2016
Q3 		$356K Hold
17
– – 0.05% 230
2016
Q2 		$260K Buy
17
+9
+113% +$206K 0.04% 237
2016
Q1 		$215K Sell
8
-16
-67% -$338K 0.03% 261
2015
Q4 		$683K Sell
24
-4
-14% -$132K 0.09% 180
2015
Q3 		$689K Buy
+28
New +$1.89M 0.1% 185

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Stoneridge Investment Partners's TPST Position: Q1 2018 in Review

Stoneridge Investment Partners sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 3 shares — an estimated $14K sold.

Stoneridge Investment Partners first reported a position in TPST in Q3 2015 and held it in 10 quarters. The position peaked at $689K in Q3 2015. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • Stoneridge Investment Partners reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Stoneridge Investment Partners sold 3 Tempest Therapeutics shares in Q1 2018, an estimated $14K.
  • Stoneridge Investment Partners first reported a position in Tempest Therapeutics in Q3 2015 and held it in 10 quarters.
  • Stoneridge Investment Partners's Tempest Therapeutics position peaked at $689K in Q3 2015.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Stoneridge Investment Partners's 13F filing for Q1 2018, filed 27 Apr 2018.